Zein decorated rifaximin nanosuspension: approach for sustained release and anti-bacterial efficacy enhancement.

IF 3 Q2 PHARMACOLOGY & PHARMACY Therapeutic delivery Pub Date : 2024-11-12 DOI:10.1080/20415990.2024.2418799

Atul Mourya, Mayank Handa, Kanchan Singh, Suresh Chintalapati, Jitender Madan, Rahul Shukla

{"title":"Zein decorated rifaximin nanosuspension: approach for sustained release and anti-bacterial efficacy enhancement.","authors":"Atul Mourya, Mayank Handa, Kanchan Singh, Suresh Chintalapati, Jitender Madan, Rahul Shukla","doi":"10.1080/20415990.2024.2418799","DOIUrl":null,"url":null,"abstract":"Aim: The goal of the present work was to formulate zein-decorated rifaximin (RFX) nanosuspension to attain sustained release as well as effectiveness against Escherichia coli (E. coli).Methods: The RFX nanosuspension was fabricated by using antisolvent addition method followed by coating using hydroalcoholic zein solution. The optimized RFX-NS and RFX-NS@zein was lyophilized for further spectroscopic evaluations. In vitro antibacterial potential was elucidated using well diffusion method whereas MIC value was determined by microbroth dilution method against E. coli for RFX-NS and pure RFX.Results: Box-Behnken Design was employed to assess the effects of independent variables on quality target product profile of RFX-NS. Optimized RFX-NS depicted particle size of 193.5 ± 4.45 nm with 76.49 ± 1.71% drug content. The significant change in particle size and zeta potential confirmed the formation of zein coated RFX-NS (RFX-NS@zein). In vitro release study depicted, 96.91 ± 1.21% release of RFX from RFX-NS in 6 h whereas 97.47 ± 1.99% RFX release was observed from RFX-NS@zein at the end of 12 h. Antibacterial assay of RFX-NS and free RFX against E. coli displayed MIC value of 15.44 ± 0.01 μg/ml and 72.96 ± 0.25 μg/ml, respectively.Conclusion: The results highlighted a significance of nanosuspension for improving the solubility of RFX and its antibacterial potential against E. coli.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2024.2418799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The goal of the present work was to formulate zein-decorated rifaximin (RFX) nanosuspension to attain sustained release as well as effectiveness against Escherichia coli (E. coli).Methods: The RFX nanosuspension was fabricated by using antisolvent addition method followed by coating using hydroalcoholic zein solution. The optimized RFX-NS and RFX-NS@zein was lyophilized for further spectroscopic evaluations. In vitro antibacterial potential was elucidated using well diffusion method whereas MIC value was determined by microbroth dilution method against E. coli for RFX-NS and pure RFX.Results: Box-Behnken Design was employed to assess the effects of independent variables on quality target product profile of RFX-NS. Optimized RFX-NS depicted particle size of 193.5 ± 4.45 nm with 76.49 ± 1.71% drug content. The significant change in particle size and zeta potential confirmed the formation of zein coated RFX-NS (RFX-NS@zein). In vitro release study depicted, 96.91 ± 1.21% release of RFX from RFX-NS in 6 h whereas 97.47 ± 1.99% RFX release was observed from RFX-NS@zein at the end of 12 h. Antibacterial assay of RFX-NS and free RFX against E. coli displayed MIC value of 15.44 ± 0.01 μg/ml and 72.96 ± 0.25 μg/ml, respectively.Conclusion: The results highlighted a significance of nanosuspension for improving the solubility of RFX and its antibacterial potential against E. coli.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Zein 修饰的利福昔明纳米悬浮液：持续释放和提高抗菌功效的方法。

目的：本研究的目的是配制经玉米蛋白装饰的利福昔明（RFX）纳米悬浮液，以实现持续释放并有效抑制大肠杆菌（E. coli）：方法：RFX 纳米悬浮液的制备采用了反溶剂添加法，然后使用水醇玉米蛋白溶液进行包衣。优化后的 RFX-NS 和 RFX-NS@zein 被冻干，用于进一步的光谱评估。采用井扩散法阐明了 RFX-NS 和纯 RFX 的体外抗菌潜力，而通过微流稀释法测定了 RFX-NS 和纯 RFX 对大肠杆菌的 MIC 值：结果：采用方框-贝肯设计法评估了自变量对 RFX-NS 目标产品质量的影响。优化后的 RFX-NS 的粒径为 193.5 ± 4.45 nm，药物含量为 76.49 ± 1.71%。粒度和 zeta 电位的明显变化证实形成了玉米蛋白包衣 RFX-NS（RFX-NS@玉米蛋白）。体外释放研究表明，RFX-NS 在 6 小时内释放了 96.91 ± 1.21% 的 RFX，而 RFX-NS@zein 在 12 小时结束时释放了 97.47 ± 1.99% 的 RFX。RFX-NS 和游离 RFX 对大肠杆菌的抗菌检测显示 MIC 值分别为 15.44 ± 0.01 μg/ml 和 72.96 ± 0.25 μg/ml：结果表明，纳米悬浮液对提高 RFX 的溶解度及其对大肠杆菌的抗菌潜力具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.